Add to ORKGMucosal gene signatures to predict response to infliximab in patients with ulcerative coliti
OBJECTIVES: Inflammatory bowel disease (IBD) is characterized by a continuous influx of leukocytes i...
Journal Article; Research Support, Non-U.S. Gov't;Substantial proportion of Crohn's disease (CD) pat...
OBJECTIVES: Inflammatory bowel disease (IBD) is characterized by a continuous influx of leukocytes i...
BACKGROUND AND AIMS: Infliximab is an effective treatment for ulcerative colitis with over 60% of pa...
Background and aims: Infliximab is an effective treatment for ulcerative colitis with over 60% of pa...
Background: While infliximab has revolutionized the treatment of ulcerative colitis, primary non-res...
Background: Infliximab (IFX) has become the mainstay of therapy of refractory Crohn's disease (CD). ...
Objective: Infliximab, a tumour necrosis factor-α (TNFα) antagonist, has advanced the management of ...
Background: Infliximab (IFX) has become the mainstay of therapy of refractory Crohn's disease (CD). ...
CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcer...
Objectives. To reveal the molecular mechanisms of ulcerative colitis (UC) and provide potential biom...
Background - In ulcerative colitis (UC), the molecular mechanisms that drive disease development and...
Ulcerative colitis (UC) arises from a complex interplay between host and environmental factors, but ...
Ulcerative colitis (UC) arises from a complex interplay between host and environmental factors, but ...
Background: Studies of the mucosal transcriptomic landscape have given new insight into the pathogen...
OBJECTIVES: Inflammatory bowel disease (IBD) is characterized by a continuous influx of leukocytes i...
Journal Article; Research Support, Non-U.S. Gov't;Substantial proportion of Crohn's disease (CD) pat...
OBJECTIVES: Inflammatory bowel disease (IBD) is characterized by a continuous influx of leukocytes i...
BACKGROUND AND AIMS: Infliximab is an effective treatment for ulcerative colitis with over 60% of pa...
Background and aims: Infliximab is an effective treatment for ulcerative colitis with over 60% of pa...
Background: While infliximab has revolutionized the treatment of ulcerative colitis, primary non-res...
Background: Infliximab (IFX) has become the mainstay of therapy of refractory Crohn's disease (CD). ...
Objective: Infliximab, a tumour necrosis factor-α (TNFα) antagonist, has advanced the management of ...
Background: Infliximab (IFX) has become the mainstay of therapy of refractory Crohn's disease (CD). ...
CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcer...
Objectives. To reveal the molecular mechanisms of ulcerative colitis (UC) and provide potential biom...
Background - In ulcerative colitis (UC), the molecular mechanisms that drive disease development and...
Ulcerative colitis (UC) arises from a complex interplay between host and environmental factors, but ...
Ulcerative colitis (UC) arises from a complex interplay between host and environmental factors, but ...
Background: Studies of the mucosal transcriptomic landscape have given new insight into the pathogen...
OBJECTIVES: Inflammatory bowel disease (IBD) is characterized by a continuous influx of leukocytes i...
Journal Article; Research Support, Non-U.S. Gov't;Substantial proportion of Crohn's disease (CD) pat...
OBJECTIVES: Inflammatory bowel disease (IBD) is characterized by a continuous influx of leukocytes i...